Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Capecitabine (Primary) ; Everolimus (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Therapeutic Use
- 07 Aug 2018 Planned End Date changed from 28 Jun 2019 to 28 Jun 2020.
- 07 Aug 2018 Planned primary completion date changed from 28 Jun 2018 to 28 Jun 2019.
- 26 Apr 2018 Planned End Date changed from 1 Feb 2018 to 28 Jun 2019.